Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

by palligoelme@gmail.com | Dec 24, 2025 | Clinical Trials

​ Conditions: Pancreatic Cancer Non-resectable Interventions: Drug: Experimental: Tunlametinib+gemcitabine+albumin paclitaxel + cetuximab β Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting Conditions: Pancreatic Cancer...

Postoperative Progressive Relaxation Exercises for Pain and Anxiety After Emergency Surgery

by palligoelme@gmail.com | Dec 24, 2025 | Clinical Trials

​ Conditions: Emergency Surgical Procedures; Postoperative Pain; Postoperative Anxiety Interventions: Behavioral: Progressive Relaxation Exercises (PRE) Sponsors: Agri Ibrahim Cecen University Completed Conditions: Emergency Surgical Procedures; Postoperative Pain;...

Functional MRI for Monitoring Progression and Assessing Trends in ILD

by palligoelme@gmail.com | Dec 24, 2025 | Clinical Trials

​ Conditions: Interstitial Lung Diseases (ILD) Interventions: Diagnostic Test: Lung MRI Protocol with Functional and Contrast-Enhanced Sequences Sponsors: University Hospital Heidelberg; German Center for Lung Research; Thoraxklinik-Heidelberg gGmbH; University...

Optimizing Reduced-Flow, Low-Volume Contrast Protocols for Cerebral Angiography in Unruptured Aneurysms

by palligoelme@gmail.com | Dec 24, 2025 | Clinical Trials

​ Conditions: Interventional Neuroradiology Interventions: Radiation: Standard (Reference); Radiation: Reduced volume – standard flow rate; Radiation: Standard volume – Reduced flow rate; Radiation: Reduced volume and flow rate Sponsors: University...

Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

by palligoelme@gmail.com | Dec 24, 2025 | Clinical Trials

​ Conditions: Diabetic Retinopathy (DR); Diabetic Macular Edema (DME); Cataract; Phacoemulfisication+IOL Implantation; Intravitreal Injection Interventions: Drug: Aflibercept (Eylea) Sponsors: Ahmad Zeeshan Jamil; Sahiwal medical college sahiwal Not yet...